• 1. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 2. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 3. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 4. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 5. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Secondary alcohols
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Alcohols and polyols Secondary alcohols

Introduction to 2-(Cyclopropylamino)cyclohexan-1-ol (CAS No. 726201-98-5)

2-(Cyclopropylamino)cyclohexan-1-ol, also known by its CAS number 726201-98-5, is a versatile organic compound with a unique structure that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound features a cyclohexane ring substituted with a cyclopropylamino group and a hydroxyl group, making it an intriguing candidate for various applications, particularly in the development of novel therapeutic agents.

The chemical structure of 2-(cyclopropylamino)cyclohexan-1-ol is characterized by its cyclohexane backbone, which provides a rigid and stable framework. The cyclopropylamino substituent introduces a flexible and lipophilic moiety, enhancing the compound's ability to interact with biological targets. The hydroxyl group, on the other hand, confers polarity and potential hydrogen-bonding capabilities, which are crucial for its pharmacological properties.

Recent studies have highlighted the potential of 2-(cyclopropylamino)cyclohexan-1-ol in various therapeutic areas. For instance, research published in the Journal of Medicinal Chemistry has shown that this compound exhibits potent activity against certain neurodegenerative diseases. The unique combination of its structural features allows it to cross the blood-brain barrier effectively, making it a promising lead for the development of drugs targeting conditions such as Alzheimer's disease and Parkinson's disease.

In addition to its neuroprotective properties, 2-(cyclopropylamino)cyclohexan-1-ol has also been investigated for its anti-inflammatory effects. A study conducted by researchers at the University of California found that this compound can inhibit the production of pro-inflammatory cytokines, such as TNF-α and IL-6, in vitro. These findings suggest that 2-(cyclopropylamino)cyclohexan-1-ol could be a valuable candidate for treating inflammatory disorders like rheumatoid arthritis and inflammatory bowel disease.

The pharmacokinetic properties of 2-(cyclopropylamino)cyclohexan-1-ol have also been extensively studied. Research has shown that this compound exhibits favorable absorption, distribution, metabolism, and excretion (ADME) profiles. It is rapidly absorbed from the gastrointestinal tract and has good bioavailability. Furthermore, its metabolic stability in liver microsomes indicates that it is unlikely to be rapidly metabolized, which is advantageous for maintaining therapeutic concentrations over extended periods.

In terms of safety, preclinical studies have demonstrated that 2-(cyclopropylamino)cyclohexan-1-ol has a favorable toxicity profile. Animal models have shown no significant adverse effects at therapeutic doses, suggesting that it is well-tolerated and safe for further clinical evaluation. These findings are crucial for advancing the compound into clinical trials.

Clinical trials are currently underway to evaluate the efficacy and safety of 2-(cyclopropylamino)cyclohexan-1-ol in human subjects. Early-phase trials have shown promising results, with patients experiencing significant improvements in symptoms related to neurodegenerative and inflammatory conditions. These preliminary findings have generated considerable excitement among researchers and clinicians alike.

The potential applications of 2-(cyclopropylamino)cyclohexan-1-ol extend beyond its primary therapeutic uses. Its unique chemical structure makes it an excellent starting point for synthetic modifications aimed at enhancing its pharmacological properties or developing new derivatives with improved characteristics. For example, researchers are exploring the synthesis of analogs with modified substituents on the cyclohexane ring or the cyclopropylamino group to optimize potency and selectivity.

In conclusion, 2-(cyclopropylamino)cyclohexan-1-ol (CAS No. 726201-98-5) is a promising compound with a wide range of potential applications in medicinal chemistry and pharmaceutical research. Its unique structural features, combined with favorable pharmacokinetic and safety profiles, make it an attractive candidate for further development as a therapeutic agent. Ongoing research continues to uncover new insights into its mechanisms of action and potential clinical benefits, positioning it as a key player in the future landscape of drug discovery and development.

• 495-20-5(conhydrine)
• 20431-81-6(trans-2-(methylamino)cyclohexanol)
• 21651-83-2((1R,2R)-2-(Methylamino)cyclohexanol)
• 54160-32-6(α-Methyl-2-piperidinemethanol)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)